Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GenVec Inc (NASDAQ:GNVC)

0.60
Delayed Data
As of 10:11am ET
 +0.01 / +1.69%
Today’s Change
0.35
Today|||52-Week Range
3.69
-67.39%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$13.8M

Company Description

GenVec, Inc. is a clinical-stage biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. It is working with other companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. It's development programs address therapeutic areas such as hearing loss, balance disorders and cancer; as well as vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, dengue fever and malaria. The company was founded in December 1992 and is headquartered in Gaithersburg, MD.

Contact Information

GenVec, Inc.
910 Clopper Road
Gaithersburg Maryland 20878
P:(240) 632-0740
Investor Relations:

Employees

Shareholders

Other institutional28.39%
Individual stakeholders15.73%
Mutual fund holders1.30%

Top Executives

Douglas J. SwirskyPresident, CEO, Secretary & Director
James Vincent LambertTreasurer, Controller & Senior Director-Finance
Douglas E. BroughChief Scientific Officer
Bryan T. ButmanSenior Vice President-Development